MDxHealth SA, a maker of noninvasive urology tests used to diagnose prostate cancer that’s struggled to gain traction as a public company (Nasdaq: MDXH), looks closer to turning an important corner.
Imaging technologies in urology have become integral tools for diagnosing and treating various urinary and reproductive system conditions. These technologies range from ultrasounds and CT scans to ...
Costs increased between 2010 and 2020 for follow-up diagnostic testing after PSA-based screening. (HealthDay News) — For patients with private insurance undergoing diagnostic testing after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results